Pro Dex Inc (PDEX) stock
PDEXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends June 30
Financials through Q1 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 18/306% below fair value
$65.66−1.76 (-2.61%)
Close on Nov 13, 2026Market cap $210.11MP/E 18.1Yield –
Pro Dex r&d expenses
Research and development expenses are spending on new products and technology.
Pro Dex's R&D Expenses for the twelve months ending Sep 30, 2026 was $3.79M, up 6.3% year over year. For fiscal 2026 it was $3.35M, down 8.0% from the year before. Over ten years it grew 10.8% a year on average. The highest annual figure on record is $4.38M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $3.35M | -8.0% |
| FY2025 | Jun 30, 2025 | $3.64M | +14.0% |
| FY2024 | Jun 30, 2024 | $3.19M | +13.7% |
| FY2023 | Jun 30, 2023 | $2.80M | -5.9% |
| FY2022 | Jun 30, 2022 | $2.98M | -32.0% |
| FY2021 | Jun 30, 2021 | $4.38M | +89.4% |
| FY2020 | Jun 30, 2020 | $2.32M | +23.0% |
| FY2019 | Jun 30, 2019 | $1.88M | -0.6% |
| FY2018 | Jun 30, 2018 | $1.89M | +54.5% |
| FY2017 | Jun 30, 2017 | $1.23M | +1.7% |
| FY2016 | Jun 30, 2016 | $1.20M | -27.8% |
| FY2015 | Jun 30, 2015 | $1.67M | +12.6% |
| FY2014 | Jun 30, 2014 | $1.48M | -17.2% |
| FY2013 | Jun 30, 2013 | $1.79M | -13.4% |
| FY2012 | Jun 30, 2012 | $2.07M | +9.5% |
| FY2011 | Jun 30, 2011 | $1.89M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Sep 30, 2026 | $1.21M | +57.6% |
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | $1.02M | +12.4% |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | $827.00K | -12.7% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $734.00K | -22.1% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $768.00K | -8.9% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $905.00K | +8.3% |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $947.00K | +24.6% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $942.00K | +19.5% |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $843.00K | +4.7% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $836.00K | +20.3% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $760.00K | +6.6% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $788.00K | +68.7% |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $805.00K | -13.3% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $695.00K | -4.3% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $713.00K | +8.4% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $467.00K | -24.1% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $929.00K | -5.2% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $726.00K | -39.5% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $658.00K | -40.4% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $615.00K | -37.8% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | $980.00K | -10.2% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $1.20M | +47.4% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $1.10M | +78.1% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $989.00K | +149.1% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $1.09M | +125.4% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $814.00K | +49.4% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $620.00K | +2.8% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $397.00K | +21.8% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $484.00K | +18.6% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $545.00K | +21.7% |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $603.00K | +7.7% |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $326.00K | -31.8% |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $408.00K | +0.2% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $448.00K | +16.1% |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $560.00K | +117.9% |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $478.00K | +71.9% |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | $407.00K | – |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $386.00K | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | $257.00K | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | $278.00K | – |
See a number that looks wrong?